Skip to main content
OpenTrials
Completed

NCT Number: NCT00214058

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ovarian Carcinoma Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Primary Peritoneal Carcinoma Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, 53792, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Recurrent ovarian or peritoneal cancer

Exclusion criteria

  • No prior chemotherapy

Treatment and study plan

carboplatin

Drug

docetaxel

Drug

Primary outcomes

  1. Safety and Efficacy

Secondary outcomes

  1. QOL

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Collaborators

  • Aventis Pharmaceuticals

Registry information

Official study title

Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma

Important dates

Study start
2002
Study completion
2006
First posted
Sep 21, 2005
Registry last updated
Nov 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.